Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Iloprost

Criteria

Inclusion Criteria:

• Completion of the 12-week treatment period of the predecessor Schering study 97218/300180

• Investigator judged iloprost aerosol therapy warranted as a suitable treatment for the respective patient

• Negative pregnancy test for females

Exclusion Criteria:

• Any condition during 12-week treatment period of the predecessor Schering study 97218/300180 that prevents participation in the follow-up safety surveillance study